Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
Explore this paper's citation graph
Summary
The development and decision-making of ICIs in the treatment of dMMR CRC is outlined and the use of these agents in earlier lines of therapy such as first-line metastatic therapy and adjuvant therapy for stage III CRC is explored.
- Type
- review
- Published
- 2020-02-10
- Cited by
- 39
- References
- 61
- OpenAlex
- https://openalex.org/W3005693093
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:212729377
Keywords
Medicine, Nivolumab, Pembrolizumab, Ipilimumab, Oncology
References
- Histopathological identification of colon cancer with microsatellite instability.
- A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints
- Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology.
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Genetic testing for high-risk colon cancer patients.
- Evolving synergistic combinations of targeted immunotherapies to combat cancer
- Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1
- Screening for Lynch Syndrome in Colorectal Cancer: Are We Doing Enough?
- The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints
- Mismatch repair and DNA damage signalling.
- Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
- The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes
- Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.
- DNA mismatch repair and cancer.
- Mechanisms and functions of DNA mismatch repair
- DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome
Cited by
- Targeted next generation sequencing of MLH1‐deficient, MLH1 promoter hypermethylated, and BRAF/RAS‐wild‐type colorectal adenocarcinomas is effective in detecting tumors with actionable oncogenic gene fusions
- Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
- Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
- DENDRITIC CELL VACCINE THERAPY FOR COLORECTAL CANCER
- Gutting it out: Developing effective immunotherapies for patients with colorectal cancer.
- Implications for the colorectal surgeon following the 100 000 Genomes Project
- Patient Age and Long-term Survival in Colorectal Cancer Patients Who Undergo Emergency Surgery
- Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
- Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy
- Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer
- CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
- Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer
- Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype
- Neoadjuvant immunotherapy in primary and metastatic colorectal cancer
- Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase short-chain in Colorectal Cancer
- Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer
- A Novel Prognostic Biomarker Panel for Early-Stage Colon Carcinoma
- Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy
- Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
- Colorectal cancer: the facts in the case of the microbiota
Related papers
- Data from Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
- 3518 POSTER Cetuximab with Irinotecan/FA/5-FU as first-line treatment in advanced gastric cancer: Preliminary results of a non-randomized multicenter AIO phase II study
- Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma.
- Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
- The role of cetuximab in the therapy of previously treated advanced colorectal cancer.
- A plain language summary from pembrolizumab plus ipilimumab following PD-1 antibody failure in melanoma.
- BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer
- Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.